Genital Inflammatory Responses in Women Living with HIV Randomized to Copper or Levonorgestrel Intrauterine Contraceptives: A secondary analysis of a randomized trial

In a secondary analysis of a randomized trial involving women living with HIV, the study found that while the copper intrauterine device (C IUC) induced broad and sustained increases in cervicovaginal cytokines among women on antiretroviral therapy, the levonorgestrel intrauterine system (LNG IUS) caused minimal inflammatory changes, suggesting LNG IUS is a less inflammatory contraceptive option for this population.

The Gist

The Big Picture: A Garden and Two Different Tools

Imagine the female reproductive tract as a garden. For women living with HIV, the health of this garden is crucial because inflammation (like weeds or overgrown brush) can make it easier for the HIV virus to spread, even if the woman is taking medication.

This study looked at two different tools used for birth control that sit inside this garden:

1. The Copper IUC: A non-hormonal device made of copper (like a copper wire).
2. The Hormonal IUS: A device that slowly releases a hormone called levonorgestrel (like a slow-release fertilizer).

The researchers wanted to know: Do these tools change the "weather" in the garden? Specifically, do they cause inflammation (a stormy, angry environment) or keep things calm?

They studied 100 women living with HIV, splitting them into two main groups:

• Group A: Women taking HIV medication (ART) that keeps the virus under control.
• Group B: Women not taking HIV medication yet, so their bodies were already fighting the virus actively.

The Starting Line: The State of the Garden Before the Tools

Before putting any devices in, the researchers took a "weather report" of the garden.

• Group B (No Medication): Their gardens were already in a state of "high alert." Because the virus was active, their bodies were naturally producing a lot of inflammatory signals (cytokines). It was like a garden that was already overgrown with weeds and buzzing with angry bees.
• Group A (On Medication): Their gardens were much calmer. The medication had suppressed the virus, so the natural inflammation was low. The garden was quiet and peaceful.

The Experiment: What Happened After Insertion?

The researchers then inserted either the Copper or the Hormonal device and checked the garden again at 3 months and 6 months.

1. What happened to Group B (No Medication)?

Since their gardens were already "stormy" and full of inflammation from the HIV, adding a birth control device didn't really change the weather.

• The Copper Device: It didn't make the storm much worse. The garden was already so active that the device didn't add much new noise.
• The Hormonal Device: It also didn't change the weather significantly.
• The Takeaway: When the garden is already chaotic, it's hard to tell if a new tool made it worse. The existing inflammation was so loud it drowned out any small changes the devices might have caused.

2. What happened to Group A (On Medication)?

This is where the results were very clear. Because their gardens were quiet to begin with, any change caused by the device was easy to hear.

• The Copper Device: When this was inserted, the garden suddenly got "noisy." The levels of inflammatory signals (cytokines) shot up significantly across the board. It was like dropping a rock into a quiet pond and causing big waves. The garden became much more active and inflamed.
• The Hormonal Device: When this was inserted, the garden stayed mostly quiet. There were very few changes in the inflammatory signals. The garden remained calm and stable.

The Conclusion: Which Tool is Quieter?

The study found that for women whose HIV is well-controlled with medication:

• The Copper IUC acts like a trigger that wakes up the immune system, causing a broad increase in inflammation.
• The Hormonal IUS acts like a gentle touch, keeping the immune system calm and not causing a significant inflammatory response.

The researchers conclude that while both methods are safe and effective for birth control, the Hormonal IUS might be the better choice for women on HIV medication if the goal is to keep the genital tract as calm and non-inflamed as possible.

Important Notes from the Study

• Safety First: The study did not say that the Copper device is "unsafe" or that it causes HIV to spread. It simply measured biological signals (inflammation). Both devices are considered safe.
• The "Why": The study suggests that the body's reaction to the Copper device depends on how "quiet" the immune system is already. If the immune system is already fighting a battle (no medication), the Copper device doesn't add much. If the immune system is resting (on medication), the Copper device wakes it up.
• What wasn't tested: The study looked at chemical signals in the fluid, not at whether women actually got infected with HIV or had clinical health problems. It measured the potential for inflammation, not the final health outcome.

Technical Summary

Problem Statement
Safe and effective contraception is critical for women living with HIV (WLHIV), yet concerns regarding the biological compatibility of contraceptive methods with antiretroviral therapy (ART) persist. While intrauterine contraceptives (IUCs), specifically copper IUCs (C-IUC) and levonorgestrel intrauterine systems (LNG-IUS), are highly effective and clinically safe regarding HIV disease progression, their impact on genital inflammation remains unclear. Genital inflammation is a known driver of HIV shedding in genital secretions, even among women on effective ART. In women without HIV, IUC insertion induces inflammatory responses, including leukocyte infiltration and cytokine upregulation. However, it is unknown whether these immune responses differ in WLHIV based on ART status, or if different IUC types elicit distinct inflammatory profiles in this population.

Methodology
This study is a secondary analysis of a double-masked, randomized controlled trial (NCT01721798) conducted in Cape Town, South Africa, between 2013 and 2016. The analysis included 100 WLHIV randomized 1:1 to receive either a C-IUC or an LNG-IUS. Participants were stratified by ART status: non-ART users (n=48) and ART users (n=52).

• Data Collection: Cervicovaginal secretions were collected via menstrual cups at baseline (pre-insertion), and at 3 and 6 months post-insertion.
• Laboratory Analysis: Twenty-eight cytokines were measured using Luminex technology and grouped into functional classes: inflammatory, chemotactic, adaptive, hematopoietic, and anti-inflammatory.
• Statistical Approach: The study employed participant fixed-effects models to compare cytokine concentrations at follow-up visits against baseline, stratified by ART status. Analyses included log10 transformations, geometric mean ratios (GMRs), and adjustments for multiple comparisons (Benjamini-Hochberg). Unsupervised hierarchical clustering and Partial Least Squares Discriminant Analysis (PLS-DA) were used to identify patterns distinguishing IUC types within the ART-using subgroup.

Key Results
The study yielded three primary findings regarding the interaction between ART status, IUC type, and genital cytokine profiles:

1. Baseline Differences by ART Status: At enrollment, non-ART users exhibited significantly higher concentrations of 21 out of 28 cytokines compared to ART users. Untreated HIV infection was associated with a state of heightened mucosal inflammation, whereas ART users had substantially lower baseline cytokine levels, consistent with viral suppression.
2. Impact on Non-ART Users: Among women not using ART, neither C-IUC nor LNG-IUS insertion resulted in significant, sustained increases in cytokine concentrations at 3 or 6 months relative to baseline. While some individual cytokines showed transient increases (e.g., MCP-1 in C-IUC users), these largely lost significance after multiple comparison adjustments. The authors suggest that the high baseline inflammation in untreated HIV may have attenuated the ability to detect additional IUC-associated immune activation.
3. Impact on ART Users: In contrast, among virally suppressed women on ART, C-IUC insertion was associated with broad and sustained increases in cytokine concentrations across multiple functional classes at both 3 and 6 months. Sixteen cytokines remained significantly elevated at 3 months, and 15 at 6 months, including IL-6, RANTES, MCP-1, MIP-1α, and G-CSF. Conversely, LNG-IUS insertion in ART users resulted in minimal cytokine changes, with only IL-5 showing a significant increase at month 3. Longitudinal analysis confirmed that C-IUC users exhibited significantly larger increases over time compared to LNG-IUS users for specific cytokines (G-CSF, IL-6, MCP-1, MIP-1α).

Significance and Claims
The paper concludes that ART status fundamentally shapes the genital mucosal immune response to IUCs in WLHIV.

• For Non-ART Users: The study suggests that the pre-existing high inflammatory state in untreated HIV may mask or minimize the additional inflammatory effects of IUC insertion.
• For ART Users: The findings indicate that C-IUCs are associated with a distinct pro-inflammatory shift in the genital tract, whereas LNG-IUS maintains a comparatively stable, low-inflammatory environment.
• Clinical Implication: While both methods remain safe and effective for contraception, the data support the use of LNG-IUS as a less inflammatory option for WLHIV on ART to minimize genital immune activation. The study emphasizes that the choice of IUC may influence the local immunologic environment, a factor relevant to HIV transmission risk, though the study did not directly measure transmission outcomes.

The authors note limitations, including the potential for missing transient inflammatory responses immediately post-insertion (as sampling began at 3 months) and the use of older ART regimens compared to current standards. They frame their results as biological signals rather than definitive clinical endpoints regarding HIV transmission risk.